Physician profile
Jackson Gao
NPI 1538663208
$26,899.64
in general payments reported to CMS, 2019-2025
15 companies · $25K in 2025
The $25K reported for 2025 was more than what 94% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $2,042 · 2025: $25K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $15K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,590 · Food and Beverage: $1,586 · Travel and Lodging: $507 · Education: $107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $15,110.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,590.00 |
| Food and Beverage | $1,585.80 |
| Travel and Lodging | $506.94 |
| Education | $106.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $11,240.81 | 2024-2025 | Lynparza, Enhertu, Imfinzi |
| Kite Pharma, INC. | $6,719.42 | 2025 | Yescarta |
| Janssen Biotech, INC. | $2,845.19 | 2025 | Rybrevant |
| Beone Medicines USA, INC. | $2,002.40 | 2025 | Tevimbra, Brukinsa |
| Beigene USA, INC. | $1,969.85 | 2024-2025 | Brukinsa, Tevimbra |
| Avyxa Pharma, LLC | $1,309.55 | 2025 | |
| Alexion Pharmaceuticals, INC. | $175.00 | 2025 | Ultomiris |
| Abbvie INC. | $157.90 | 2025 | |
| Genentech USA, INC. | $135.14 | 2025 | Tecentriq, Polivy, Itovebi |
| Astellas Pharma US INC | $113.10 | 2024-2025 | Xospata, Vyloy |
| Tempus Ai, INC | $107.10 | 2025 | Xt Cdx |
| Accord Healthcare, INC. | $88.66 | 2025 | |
| Iovance Biotherapeutics, INC. | $20.74 | 2025 | Amtagvi |
| Agios Pharmaceuticals, INC. | $14.78 | 2025 | Pyrukynd |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jackson Gao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.